What Combinostics does

Combinostics Oy (founded 2014, headquartered in Tampere, Finland, with a US subsidiary, Combinostics US Inc., in Boston) develops AI-driven neuroimaging diagnostic software for neurodegenerative diseases. Its core offering is the cloud-based cNeuro platform, which combines two integrated applications: cMRI, which performs fully automated quantification of brain MRI scans (detecting atrophy, white-matter abnormalities, and benchmarking against reference data); and cDSI (Clinical Decision Support), which uses a patented disease-state-fingerprint machine-learning method to compare a patient's imaging biomarkers against more than 2,000 confirmed cases of Alzheimer's disease, frontotemporal dementia, vascular dementia, and cognitively normal patients to support differential diagnosis and predict disease progression. The platform also includes cPET for PET image quantification and cDAT for DAT SPECT quantification (released in Europe in December 2023). Marketing materials position Combinostics as the only vendor offering a complete AI solution spanning the full patient-care pathway for major neurological disorders, integrating imaging biomarkers with clinical, neuropsychological, and demographic data.

The company sells cNeuro primarily through enterprise field sales to memory clinics, neurology departments, radiology departments, and nuclear-medicine units within hospitals and healthcare systems (named reference customers include Karolinska University Hospital, CIMF Fribourg, and Unilabs Sweden), supplemented by strategic technology integrations with GE Healthcare, Siemens Healthineers, and Sectra that distribute the platform through major imaging-vendor installed bases. Revenue is generated via cloud-based recurring subscription, with separate US and EU regional cloud portals for data-hosting compliance. The company remained privately held and small-scale (11-50 employees) until January 2, 2025, when it was acquired by SyntheticMR AB for EUR 4.3 million (~$5.03 million), mostly in cash with the remainder via promissory note and convertibles, and now operates as a wholly-owned subsidiary within SyntheticMR's AI-based neuroimaging portfolio.

Combinostics participates in industry conferences (notably RSNA), maintains thought-leadership content on neuroimaging and AI, and operates a free-trial and demo-request funnel. The company's addressable market — AI-assisted brain diagnostics — is projected to grow from $1.74 billion in 2024 to $5.46 billion in 2029, with the broader brain AI-assisted diagnosis market forecasted at $6.84 billion by 2030 at a 25.5% CAGR. Independent revenue figures are not publicly disclosed; the modest acquisition valuation relative to a high-growth end market implies sub-$5M standalone ARR on the eve of the SyntheticMR transaction.

Name

Combinostics

Legal name

Combinostics Oy

Website

https://combinostics.com

Company type

Private

Founded year

2014

Operating status

Acquired

Headcount range

11–50 employees

Short description

Combinostics is a Finland-based medical technology company that provides AI-powered neuroimaging diagnostic support for neurodegenerative diseases via its cloud-based cNeuro platform, sold to hospitals, memory clinics, and radiology/nuclear-medicine departments across Europe and the US.

Ownership category

akta.pro rank

Product category

Medical Imaging AI Software

NAICS

Computer Systems Design and Related Services (54151), Other Computer Related Services (541519)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Radiology AI, CAD & Advanced Visualization Software (HLAHABAJ)

akta.pro secondary industries

Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO), Medical Imaging AI (HDAAAEAH), AI Orchestration & Imaging Analytics Platforms (Model Management/Triage) (HLACALAG)

Keywords

• Neuroimaging software
• AI diagnostic platform
• Brain MRI quantification
• Neurodegenerative disease diagnostics
• Clinical decision support

Headquarters

HQ city

Tampere

HQ country

Finland

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Infrastructure, Marketing or Sales, Operations

Revenue model

1. cNeuro Platform Subscription: Cloud-based AI diagnostic platform offered as subscription service to healthcare providers, hospitals, and medical imaging centers for neuroimaging analysis and neurodegenerative disease diagnosis support.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Combinostics develops and sells the cloud-based cNeuro platform, an AI-driven diagnostic suite for the early detection, diagnosis, and management of major neurodegenerative disorders. The platform combines cMRI (fully automated brain MRI quantification with validated imaging biomarkers) and cDSI (AI-supported differential diagnosis using patented disease state fingerprint technology that compares a patient's data to 2,000+ confirmed neurodegenerative disease cases), along with cPET and cDAT modules for nuclear medicine imaging quantification. The solution is sold to hospitals, memory clinics, radiology departments, and medical imaging centers to support neurologists, radiologists, and geriatricians in making earlier and more confident diagnostic and disease-progression decisions.

Product overview

Combinostics offers a complete AI solution for the early detection, diagnosis, and management of major neurological disorders through its cloud-based cNeuro platform. The platform consists of two main integrated applications: cMRI (fully automated MRI quantification) and cDSI (AI-supported differential diagnosis and disease progression prediction). cMRI provides fully automated brain MRI analysis while cDSI combines this imaging data with other patient data including biomarkers, clinical and neuropsychological tests, and demographic data using AI methods and patented disease state fingerprint technology. The platform supports Neurology, Nuclear Medicine, and Radiology workflows, enabling radiologists and clinicians to communicate more effectively across different organizations. Additional modules include cPET for PET image quantification and cDAT for DAT SPECT imaging analysis.

Differentiator

Problem solved

Functional benefit

Brands

• cNeuro: A complete cloud-based AI solution for early detection, diagnosis, and management of major neurological disorders. Combines cMRI and cDSI applications.
• cMRI
• cDSI
• cPET
• cDAT

Products and services

• cNeuro Platform Cloud-based AI platform that connects the cMRI and cDSI applications with multiple external data sources for comprehensive patient management in neurological disorders, sold to hospitals, memory clinics, and medical imaging centers.
• cNeuro cMRI Fully automated MRI quantification application that provides biomarker detection and reporting, evaluates brain atrophy and structural changes, quantifies white matter abnormalities, and compares results to reference data; usable as a standalone application for radiology departments and imaging centers.
• cNeuro cDSI (Clinical Decision Support) AI-supported differential diagnosis and prediction system for neurodegenerative diseases that combines imaging data with clinical data, biomarkers, neuropsychological tests, and demographic data using patented disease state fingerprint technology for neurologists and memory clinics.
• cNeuro cPET Application for quantification and analysis of PET images used in nuclear medicine departments for neurological disorder assessment.
• cNeuro cDAT Application for quantification of DAT SPECT images for dopamine transporter imaging in neurodegenerative disease diagnosis, released in Europe in December 2023.
• Dementia Differential Analysis Report Report generated from MRI data using cDSI's proprietary machine learning method that measures similarity of disease-specific imaging biomarker values against 2,000+ confirmed neurodegenerative disease patients, supporting diagnoses including Alzheimer's disease, frontotemporal dementia, vascular dementia, and cognitively normal.

Quantifiable outcome

• Compares patient data to 2,000+ patients with confirmed neurodegenerative disease for accurate differential diagnosis

Named customers3 records

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature4 records

Partnerships

Four partnerships are on record, tiered core.

• SyntheticMR ABcoreStrategic or Co-development Partner · 28 November 2024Acquisition by SyntheticMR AB in January 2025 for EUR 4.3 million to integrate Combinostics' cNeuro platform and strengthen SyntheticMR's AI-based neuroimaging capabilities in the European market.
• GE HealthcarecoreTechnology or IntegrationStrategic technology partnership for integration of cNeuro AI diagnostic platform with GE Healthcare medical imaging systems, enabling combined imaging and AI analysis solutions for healthcare providers.
• Siemens HealthineerscoreTechnology or IntegrationTechnology partnership integrating cNeuro platform with Siemens Healthineers imaging equipment and software solutions for comprehensive neuroimaging diagnostics.
• SectracoreTechnology or IntegrationPartnership integrating cNeuro AI diagnostics with Sectra medical imaging IT solutions for enhanced radiology workflow and diagnostic capabilities.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• Aidoc: Aidoc is a leading clinical AI platform spanning multiple imaging modalities including neurological AI for stroke triage; broader portfolio than Combinostics but overlapping in hospital neuroimaging AI adoption.
• Viz.ai: Viz.ai's hyperacute stroke workflow AI overlaps in the neurology imaging AI category and competes for the same hospital informatics budgets, though focused on acute rather than neurodegenerative use cases.
• Qure.ai: Qure.ai offers FDA-cleared AI for head CT/MRI including neurodegeneration-adjacent use cases; competes for similar radiology AI procurement opportunities globally.
• RapidAI: RapidAI focuses on neuroimaging AI for stroke and other conditions, sharing the hospital neuroimaging AI install footprint with Combinostics even though its modality mix differs.

Emerging players

• Quibim: Quibim offers AI-based quantitative imaging biomarkers for brain MRI and other organs, with similar disease-state fingerprinting approaches to neurodegenerative disease diagnosis.
• Cortechs.ai: Cortechs.ai develops NeuroQuant and similar quantitative brain MRI tools, historically the incumbent in the brain volumetry space where Combinostics' cMRI now competes.
• Pixyl: Pixyl provides AI-driven brain MRI biomarkers for MS and neurodegeneration, a smaller direct competitor targeting the same neuroimaging AI budget at hospitals.
• Annalise.ai: Annalise.ai provides comprehensive radiology AI including brain CT/MRI analysis, competing for radiology department AI budgets and broader diagnostic imaging workflows where Combinostics is sold.

Direct peers

• icometrix: icometrix provides AI-powered MRI brain quantification solutions (icobrain) for multiple sclerosis and dementia; it is the most directly comparable neuroimaging AI platform to Combinostics' cNeuro cMRI.
• SyntheticMR: Parent company of Combinostics since January 2025, offering SyMRI quantitative MRI software; combines product overlap and now corporate integration with Combinostics' cNeuro platform.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xtwitter.com/combinostics
• Facebookfacebook.com/combinostics
• LinkedInlinkedin.com/company/combinostics

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds5 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Combinostics